Norman L Foster

List of Publications by Year
in descending order

21 papers	1,756 citations	758635 12 h-index	839053 18 g-index
22 all docs	22 docs citations	22 times ranked	2956 citing authors

#	Article	IF	Citations
1	Evaluating the Impact of Cochlear Implantation on Cognitive Function in Older Adults. Laryngoscope, 2022, 132, .	1.1	16
2	How good are medical and death records for identifying dementia?. Alzheimer's and Dementia, 2022, 18, 1812-1823.	0.4	3
3	Overall and sex-specific risk factors for subjective cognitive decline: findings from the 2015â€“2018 Behavioral Risk Factor Surveillance System Survey. Biology of Sex Differences, 2022, 13, 16.	1.8	9
4	Changes in the Auditory Association Cortex in Dementing Illnesses. Otology and Neurotology, 2020, 41, 1327-1333.	0.7	6
5	Quality improvement in neurology. Neurology, 2019, 93, 705-713.	1.5	29
6	Relationship between ¹⁸F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults. Clinical Neuropsychologist, 2017, 31, 531-543.	1.5	13
7	The impact of Î²-amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts. Neurodegenerative Disease Management, 2017, 7, 107-117.	1.2	1
8	Overexpression of Mutant Amyloid-Î² Protein Precursor and Presenilin 1 Modulates Enteric Nervous System. Journal of Alzheimer's Disease, 2015, 44, 1263-1278.	1.2	57
9	Short-Term Practice Effects and Brain Hypometabolism: Preliminary Data from an FDG PET Study. Archives of Clinical Neuropsychology, 2015, 30, 264-270.	0.3	17
10	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer's and Dementia, 2015, 11, 757-771.	0.4	199
11	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 Î²-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	4.5	87
12	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimer's and Dementia, 2015, 11, 1050-1068.	0.4	98
13	Clinical use of amyloidâ€positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 358-367.	1.2	33
14	Coverage With Evidence Development. JAMA Neurology, 2014, 71, 399.	4.5	9
15	Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. , 2014, 10, 503-508.		6
16	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.4	176
17	The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's and Dementia, 2010, 6, 221-229.	0.4	464
18	Commentary on â€œA roadmap for the prevention of dementia II. Leon Thal Symposium 2008.â€•Innovations in care that advance Alzheimer's disease drug development. , 2009, 5, 159-162.		0

#	Article	IF	Citations
19	Realizing the potential of positron emission tomography with ¹⁸Fâ€fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, S29-36.	0.4	25
20	Strategies for using Molecular Neuroimaging in Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 87-95.	1.0	0
21	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 2007, 130, 2616-2635.	3.7	508